Positive Phase II Lung Cancer Data to Be Presented at ASCO Support Recently Opened Registrational Phase IIb Trial for …

Published June 5, 2010

Positive Phase II Lung Cancer Data to Be Presented at ASCO Support Recently Opened Registrational Phase IIb Trial for …
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced positive data from a Phase II clinical trial treating front-line non-small cell lung cancer (NSCLC) patients with bavituximab in combination with paclitaxel and carboplatin. 43% (21 of 49 patients …